Shaila D. Ghanekar, W. W. Miller, C. Meyer, Kevin J Fenelon, Alvin Lacdao, T. Zesiewicz
{"title":"正在开发的治疗弗里德里希共济失调的孤儿药：重点关注奥那韦洛龙","authors":"Shaila D. Ghanekar, W. W. Miller, C. Meyer, Kevin J Fenelon, Alvin Lacdao, T. Zesiewicz","doi":"10.2147/DNND.S180027","DOIUrl":null,"url":null,"abstract":"Abstract Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.","PeriodicalId":93972,"journal":{"name":"Degenerative neurological and neuromuscular disease","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2019-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DNND.S180027","citationCount":"3","resultStr":"{\"title\":\"Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone\",\"authors\":\"Shaila D. Ghanekar, W. W. Miller, C. Meyer, Kevin J Fenelon, Alvin Lacdao, T. Zesiewicz\",\"doi\":\"10.2147/DNND.S180027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.\",\"PeriodicalId\":93972,\"journal\":{\"name\":\"Degenerative neurological and neuromuscular disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2019-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/DNND.S180027\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Degenerative neurological and neuromuscular disease\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.2147/DNND.S180027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Degenerative neurological and neuromuscular disease","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.2147/DNND.S180027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
Abstract Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
